Catheter Precision Prices an Aviation Pivot, Not 68 Million Shares of Supply

Run scope: U.S. market short opportunities only. Research timestamp: July 20, 2026, 14:15 UTC. This is a conditional research expression, not personalized financial advice.

Opportunity Ranking

Rank	Idea	Discovery Lane	Why It May Be Best Now	Evidence Freshness	Catalyst Window	Near-Term >5% Move Case	Asymmetry	Main Reason to Reject
1	Short `VTAK` common	U.S. microcap / preferred conversion / reverse-split financing	$1.33M live equity value sits under a registration for 68.07M shares; the 10-Q says cash is insufficient for current operations and preferred conversion could dwarf the existing denominator.	High: June S-1, March 10-Q, July 20 quote	Days to weeks: resale activity, conversion notices, Nasdaq response, or the next financing filing	A move from $0.4933 to $0.4686 is -5%; a registration or conversion disclosure can move a $1.3M equity value quickly.	High mechanical supply, but execution is fragile	Reject if live locate is unavailable or the company produces non-dilutive cash sufficient to fund operations
2	Short `HTZ` common	U.S. large-cap distressed credit / share lending / PIK notes	Hertz loaned 37.04M shares to an underwriter at a $2.70 public offering price while issuing 6.75% PIK exchangeable notes with a $3.58 exchange price. The structure creates real supply, but the stock is already below both anchors.	High: June 24-29 SEC filings, July 20 quote	Weeks to the next operating and debt disclosure	From $1.76, a 5% move is $1.672; another guidance or liquidity shock could test it, but much of the first repricing is spent.	Strong structure, weaker entry asymmetry	Existing Hertz coverage and price already below offering reference reduce novelty and edge
3	Short `VIVK` common	U.S. SEPA / convertible resale / reverse-split financing	Vivakor registered 40.69M resale shares against 4.30M common shares outstanding and separately has a $100M SEPA that buys at a discount.	Medium-high: June S-1, May 10-Q, July 20 quote	Weeks to months: conversion and SEPA draw disclosures	A move from $1.86 to $1.767 is -5%; the stock already fell 17.7% intraday, making chase risk material.	Large potential supply, but much is conditional	A 200-for-1 reverse split and volatile tape make the denominator and borrow hard to model

Selected opportunity: Short VTAK common, only with a confirmed locate and defined-risk alternative if available.

Why this one now: VTAK combines the freshest live price dislocation with an unusually explicit denominator bridge. The SEC’s June registration covers 68.07M shares, while the 10-Q reports 2.69M common shares outstanding as of May 8 and says current cash is insufficient to fund operations. That is not proof that all registered shares will be sold. It is proof that the market is pricing an operating pivot while the capital structure contains a very large, observable claim on the common.

Why it can dump >5% soon: At $0.4933, a $0.0247 decline is already 5%. A resale, preferred conversion, reverse-split action, or financing update can change the available supply in a stock with only about $1.33M of quoted equity value. The low price also makes a squeeze or halt a live counter-risk.

What should surprise the reader: The 68.07M registration is not merely a headline dilution number. The company’s own 10-Q says issued preferred stock could represent 2,167% of the May common count, and all existing plus potential future preferred could represent 10,758%. Those are contractual maximums, not a forecast. The surprise is the gap between what is legally registered and what the current market value implies, not a claim that every share must appear tomorrow.

The Setup

Catheter Precision is presenting a broader platform that includes cardiac electrophysiology and private aviation assets. The tape is valuing that pivot at roughly $1.33M of common equity. The filings describe a company with $441,000 of cash at March 31, 2026, $1.1M of cash as of May 8, quarterly revenue of $656,000, a $1.69M quarterly net loss, and substantial doubt about continuing as a going concern. March 31 10-Q

The Mispricing

Known facts: The live market snapshot showed VTAK at $0.4933 on July 20, 2026 at 14:13 UTC, down 12.46% from the prior close, with market capitalization near $1.33M and intraday volume about 706,032 shares. The June 18 S-1 registers 68,067,042 shares for resale. The 10-Q reports 2,692,473 common shares outstanding as of May 8. SEC S-1

Inference: The market may be treating the aviation acquisition and device portfolio as a clean equity story while discounting the preferred stack as a distant legal possibility. The short thesis is that the financing machinery is closer to the price than the narrative implies because the company itself says current cash is inadequate.

What this is not: Registration is potential supply, not immediate float. Preferred conversion is not the same as a completed sale. A low market cap can be a data artifact after corporate actions. The short cannot be justified by arithmetic alone.

Price

Item	Value	Timestamp / source	Interpretation
VTAK price	$0.4933	July 20, 2026, 14:13 UTC, market-data snapshot	Current reference level, not an execution price
Market capitalization	About $1.33M	Same snapshot	Approximate and potentially stale relative to post-financing shares
Intraday volume	About 706,032 shares	Same snapshot	Roughly 26% of the May 8 common count, before considering new issuance
Registered resale shares	68.07M	June 18 SEC S-1	Potential supply, not confirmed float
Preferred conversion floor	$0.35	April-June financing documents	Filing anchor and bottom-case reference, not a price target guarantee

At $0.4933, the June registration equals roughly 25.3 times the May 8 common count. The calculation is a capacity ratio. It does not imply 25.3 times dilution will occur.

Positioning

The strongest positioning evidence is structural, not a verified short-interest number. The registration allows selling stockholders to dispose of shares issued for financing and acquisitions. Series D Preferred is convertible into up to 31.51M common shares at the $0.35 floor. Series C-1 and C-2 each represent 9.91M shares at that floor. The 10-Q states that existing preferred conversion could equal 2,167% of the May common count and that existing plus potential future preferred could equal 10,758%.

Live short interest, borrow availability, borrow cost, options liquidity, and dealer flow were not verified in this run. Positioning therefore scores 3/5, not 5/5. A locate is a hard gate. No locate means no trade.

Catalyst

The catalyst is a sequence rather than one scheduled earnings date:

A selling stockholder files or begins selling registered shares.
Preferred conversion or a share-count update makes the denominator observable.
The company discloses another financing because the May 8 cash balance was not sufficient for current operations.
Nasdaq or the company takes reverse-split action after continued sub-$1 trading.
The next quarterly filing either confirms actual issuance and burn or disproves the near-term supply path.

The cheapest disconfirming test is the next filing that reports actual common shares outstanding, cash raised, and operating cash burn. A new customer, aviation contract, or device-development headline is not enough to invalidate the short unless it comes with cash economics or non-dilutive funding.

Payoff Map

The expression is a conditional short, not an instruction to sell borrowed stock. The preferred alternative is a liquid put or put spread if listed and economically usable. The stock is capable of halts, 50% squeezes, and borrow recalls.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Time Horizon	Conditions Required	Evidence Quality
Top Case for Short	35%	$0.30	+39.2% gross short return	2-8 weeks	Registered selling or conversion becomes visible, cash remains tight, and no non-dilutive financing offsets it	Medium
Base Case	45%	$0.40	+18.9% gross short return	1-8 weeks	Stock grinds toward the $0.35 conversion floor as the market discounts potential supply without a single large takedown	Medium
Bottom Case for Short	20%	$0.80	-62.2% gross short return	Any time	Clinical/device news, aviation contract, non-dilutive cash, reverse-split squeeze, or borrow failure drives a disorderly rebound	Low to Medium
Invalidation / Stop Condition	n/a	Cover above $0.80 or on credible non-dilutive funding	n/a	Immediate	The market absorbs the registered supply while operating evidence materially improves, or execution conditions deteriorate	Medium

Probability-weighted expected value: Using the scenario marks, the probability-weighted price is $0.405. Relative to $0.4933, that is an estimated 17.9% price decline, or approximately 17.9% gross short payoff before borrow, fees, slippage, and gap risk. This is scenario arithmetic, not a forecast.

Current market price / level: $0.4933.

Timestamp: July 20, 2026, 14:13 UTC.

Primary instrument: VTAK common stock, conditional on locate.

Alternative expressions considered: Liquid put or put spread if available; otherwise no trade. A naked short is inappropriate when borrow and squeeze data are unavailable.

Confidence: Medium-low. Filing evidence is strong; execution evidence is incomplete.

What Would Prove This Wrong

The next filing shows stable common shares, materially lower burn, and non-dilutive cash sufficient to fund operations.
Selling-stockholder resale activity is absent and the registered securities remain contractually blocked.
The company produces operating revenue and cash economics that justify the aviation and device valuation without further common issuance.
VTAK closes above $0.80 on fundamental news while borrow remains available.
Live borrow is unavailable, too expensive, or recalled. That invalidates the trade expression even if the capital-structure thesis remains true.

Risk Audit

Strongest counterargument: The preferred securities may finance an acquisition that creates a viable aviation platform. The registration may be precautionary, and selling stockholders may not sell immediately. In a $1.3M equity value, one contract or reverse split can dominate the tape.

Most fragile assumption: That financing supply becomes observable before operating news changes the valuation.

What the market may already know: The S-1 is public and the stock has already fallen sharply. The easy arithmetic may be crowded.

What could make the trade lose money even if the thesis is directionally right: A reverse split can raise the nominal price and trigger momentum buying. A financing can be announced as a bullish acquisition. A borrow recall can force covering at the worst price. A halt can turn a small position into a gap loss.

Liquidity / execution risks: The quote is thin, spreads can widen, and the apparent market cap may not reconcile to post-financing shares. Use limit orders only. Do not short an unlocatable share.

Leverage risks: The downside is open-ended. A 50% adverse move is plausible. Position size must be sized to that loss, not to the nominal market cap.

Information reliability risks: The quote and market cap are a live provider snapshot. SEC filings are primary, but the latest full operating data is March 31 and the share count is May 8. Borrow, short interest, options, and dealer flow were not verified.

Invalidation trigger: A close above $0.80 on credible operating or financing news, or any evidence that the company can fund operations without registered common supply.

Publish / revise / reject recommendation: Publish as a Short Note / conditional short only. Do not represent it as an executable trade without a live locate.

Bottom Line

VTAK is not shortable because it is small or because its aviation pivot sounds promotional. It is interesting because a $1.33M quoted common value sits beneath a 68.07M-share resale registration, a preferred stack that can overwhelm the existing denominator, and an explicit going-concern warning. The bear case is still conditional. The next actual share-count and cash-flow filing matters more than the prospectus maximum. Until that evidence arrives, the correct posture is no-locate, no-trade, staged risk only.

Research Quality Scorecard

Criterion	Score	Rationale
Market disagreement	5	Clear tension between aviation/device narrative and registered financing supply
Evidence base	5	Fresh SEC S-1 and 10-Q data plus live quote snapshot
Positioning and flows	3	Structural supply is documented; live borrow, short interest, options, and dealer flow are missing
Catalyst path	4	Resale, conversion, financing, reverse-split, and next filing paths are observable
Payoff architecture	4	Defined scenario downside with asymmetric squeeze risk explicitly modelled
Invalidation discipline	5	Price, funding, share-count, and execution invalidators are monitorable
Differentiated insight	5	The key is the denominator bridge, not generic biotech or aviation pessimism
Client value	4	Useful as a conditional risk map even if no trade is taken
Total	35/40	Publishable as a Short Note, not a no-conditions trade call

Sources

Source	Tier	Date / freshness	Used for
Catheter Precision June 18 S-1	Tier 1, SEC	Filed June 18, 2026	68.07M registered shares, preferred conversion terms, $0.35 floor
Catheter Precision March 31 10-Q	Tier 1, SEC	Filed May 15, 2026	Cash, revenue, loss, going-concern language, denominator scenarios
Catheter Precision February 8-K	Tier 1, SEC	Filed February 2026	Conversion mechanics and floor-price condition
Hertz June 29 8-K	Tier 1, SEC	Filed June 29, 2026	Rejected candidate: 37.04M share loan and termination mechanics
Vivakor June S-1/A	Tier 1, SEC	Filed June 2026	Rejected candidate: 40.69M resale shares and $100M SEPA

Packaging Notes

U.S.-short scope is explicit.
No CVR-led setup was selected.
The current target folder and repo-wide ticker/headline scan found no prior VTAK primary article.
The article preserves all reader-facing tables as Markdown.
Borrow, short-interest, options, dealer-flow, and same-session share-count gaps are disclosed rather than inferred away.

Illustration Prompt

Create a realistic, high-value, high-end elite, beautiful master editorial illustration for The Mispricing Desk about Catheter Precision (VTAK): a tiny common-equity market value beneath a towering, precise stack of SEC prospectus pages labelled 68.07M registered shares, $0.35 conversion floor, 2,167% issued preferred, and 10,758% potential preferred. On one side, show a clean white cardiac mapping device and a discreet private-aviation silhouette, representing the operating-pivot narrative. On the other side, show a brass scale overwhelmed by convertible preferred certificates and a thin red ticker strip marked VTAK $0.4933. The central metaphor is a small denominator carrying a much larger legal claim, with a narrow blue beam of cash labelled $1.1M fading into shadow. Mood: forensic, restrained, institutional, skeptical. Palette: graphite, surgical white, cold blue, muted copper, off-white paper, and one red warning accent. No cartoon bulls or bears, no rockets, no generic financial chart, no meme aesthetics. The image should look like a cover feature for The Economist, Barron's, or Bloomberg Markets. Include a subtle but clear watermark or text reading The Mispricing Desk.